Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mirna Chehade

Pediatric Gastroenterology New York, NY Medical Doctor

NPI 1447229190 CMS profile 156137

1 Gustave L Levy Pl, Box 1200, New York, NY 10029

Open in the dashboard

General payments

$216,962

230 records reported · program years 2019–2025

Research payments

$109,704

Paid to them · 194 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$943,838 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Mirna Chehade of New York, NY is reported in the CMS Open Payments database as having received $216,962 across 230 general payments and $109,704 in research payments paid to them. Separately, studies naming them as principal investigator received $943,838 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pediatric Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $63,421 52
2025 Research $27,335 37
2024 General $44,866 92
2024 Research $42,307 62
2023 General $35,806 30
2023 Research $12,171 29
2022 General $25,750 20
2022 Research $14,524 24
2021 General $15,145 7
2021 Research $5,939 16
2020 General $22,756 22
2020 Research $4,194 19
2019 General $9,218 7
2019 Research $3,234 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mirna Chehade
  • Pediatric Gastroenterology median
  • Middle half of Pediatric Gastroenterology
  • National median

In program year 2025, general payments to Mirna Chehade were reported at $63,421. Among 1,132 Pediatric Gastroenterology profiles paid that year, the median was $194 and the middle half received between $81 and $540.

Show as a table
Year Mirna Chehade Pediatric Gastroenterology median Middle half National median
2019 $9,218 $131 $41–$311 $163
2020 $22,756 $79 $23–$223 $114
2021 $15,145 $104 $32–$321 $132
2022 $25,750 $125 $37–$331 $149
2023 $35,806 $169 $55–$440 $160
2024 $44,866 $196 $73–$563 $164
2025 $63,421 $194 $81–$540 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $89,327 143 payments
  2. Genzyme Corporation $64,347 19 payments
  3. E.R. Squibb & Sons, L.L.C. $12,917 8 payments
  4. AstraZeneca Pharmaceuticals LP $12,637 16 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $12,295 6 payments
  6. Regeneron Healthcare Solutions, Inc. $12,097 13 payments
  7. Shire North American Group Inc $4,907 5 payments
  8. Celgene Corporation $4,124 10 payments
  9. Adare Pharmaceuticals, Inc. $2,894 8 payments
  10. AstraZeneca UK Limited $1,167 1 payment
  11. Other $250 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $158,214 59 payments
  2. Travel and Lodging $48,829 114 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,250 7 payments
  4. Education $2,967 6 payments
  5. Food and Beverage $2,703 44 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $59,526 110 payments
  2. DUPIXENT Immunology And Inflammation $37,338 44 payments
  3. DUPIXENT Immunology $28,788 9 payments
  4. FASENRA Respiratory $3,880 4 payments
  5. EOHILIA $2,670 3 payments
  6. TEZSPIRE $2,283 2 payments
  7. FASENRA Respiratory $1,373 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $107,954 192 payments
  2. Genzyme Corporation $1,750 2 payments

Records

424 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Gastroenterology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record